

## THE PROTOCOL RELATING TO THE MADRID AGREEMENT CONCERNING THE INTERNATIONAL REGISTRATION OF MARKS

## FINAL DISPOSITION ON STATUS OF A MARK

## -STATEMENT OF GRANT OF PROTECTION FOLLOWING A PROVISIONAL REFUSAL-

## Rule 18ter(2)

Swedish Intellectual Property Office Telephone: Design and Trademark Department Box 530 S-826 27 SÖDERHAMN Sweden  II. Number and wording of the international registration which is subject of the reference CHEMISTRY	int + 46 8 782 28 00  fusal 1536673, SKIN
	fusal 1536673, SKIN
The mark is protected for some only of the goods and services. All procedures be completed; protection is granted to the mark that is the subject of this internation following goods and/or services (Rule 18ter(2)(ii)):  5: Medicated skin care preparations; medicated dermatological preparations and care preparation; medicated nail care preparations; medicated eye lash care preparations; medicated body skin care preparations; medicated skin care preparations; medicated skin care preparations, bleaching agents, blenders, clarifiers, cleansers, correcting agents, or gels, lighteners, liquids, lotions, masks, moisturizers, sunblocks, sunscreens, ser skin care mixtures applied to skin for smoothing skin surface, or for improving diminishing wrinkles, blood vessels, pores and dead skin cells; pharmaceutical pskin protection and skin health restoration; preparations for use in the treatment skin and scalp creams; pharmaceutical products and preparations for use in derm supplements; cosmeceuticals, namely, medicated skin cleansers, toners, moistur creams, and lotions for the face and body; pharmaceutical preparations for use in preparations for skin care, skin treatment, skin protection and skin health restorations.	d substances; medicated hair parations; medicated eyebrow preparations, namely, creams, emollients, exfoliants, rums, and toners; medicated tone and color, or for preparations for skin treatment, t of dermatosis and for use as matology; dietary and nutritional rizers, rejuvenators, rehydrating in dermatology; pharmaceutical
IV. Date of which the statement was pronounced: 28/07/2022	
V. Signature by the Office:	